XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
New molecules that accelerate chemical reactions for manufacturing drugs
Aug 19, 2005, 22:41, Reviewed by: Dr.

"For more than a century, most catalysts were prepared using chemical compounds called phosphines," said Guy Bertrand, the lead author of the study and Distinguished Professor of chemistry. "But in the 1990s, carbenes were found to be useful to make catalysts. The new carbenes we have prepared in the laboratory are such that they protect the metals to which they bind, making the metal catalysts more stable and longer lasting."

 
Chemists at the University of California, Riverside have synthesized a new class of carbenes � molecules that have unusual carbon atoms � that is expected to have wide applications in the pharmaceutical industry, ultimately resulting in a reduction in the price of drugs.

Called cyclic alkyl amino carbenes or CAACs, the molecules attach themselves to metals, such as palladium, to form highly efficient catalysts that allow chemical transformations otherwise considered impossible. The carbenes modulate the properties of the metals to which they are bound and can facilitate and speed up reactions involving their use.

Study results appear in the Angewandte Chemie International Edition, and were published online Aug. 1.

A carbene is a molecule that has a carbon atom with six electrons instead of the usual eight. Because of the electron deficiency, carbenes are highly reactive and usually unstable in nature.

In their paper, the UCR chemists discuss a set of chemical reactions involving the use of catalysts other than those that are CAAC-based. The authors note that these catalysts need strong heating to be effective. They add that the CAAC-based catalysts, on the other hand, can be used not only at room temperature but also in smaller amounts than is necessary for the other catalysts.

"For more than a century, most catalysts were prepared using chemical compounds called phosphines," said Guy Bertrand, the lead author of the study and Distinguished Professor of chemistry. "But in the 1990s, carbenes were found to be useful to make catalysts. The new carbenes we have prepared in the laboratory are such that they protect the metals to which they bind, making the metal catalysts more stable and longer lasting."

Because nitrogen atoms stabilize a carbene when they are adjacent to it, chemists believed until now that two nitrogen atoms were necessary in a carbene to make efficient catalysts. But having two nitrogen atoms also imposes structural limitations at the center of the carbene.

The carbenes synthesized by the UCR chemists has only one nitrogen atom, which lends the molecule a far more flexible structure. In effect, the carbenes are bigger at the metallic center of the catalyst, a feature that improves the efficiency of the catalyst.

"We started this project nearly two years ago," said Vincent Lavallo, an undergraduate researcher in Bertrand's laboratory and the first author of the paper. "The carbene-based catalysts we report can simplify complex chemical preparations. Further, just mild temperatures are needed for the catalyst to be effective. Because of the catalyst's longevity, you need only a small amount to achieve your final product. All of this can dramatically reduce the cost of manufacturing drugs, given that pharmaceutical companies are increasingly using carbene-supported catalysts for their chemical reactions."

Bertrand's research group plans to continue to modify the new carbenes to find more efficient catalysts. "We're looking also for new catalytic reactions facilitated by these new carbene metal complexes," Lavallo said. "The CAACs have made the field of carbene chemistry more exciting than ever."
 

- Study results appear in the Angewandte Chemie International Edition, and were published online Aug. 1.
 

University of California - Riverside

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

Yves Canac, Carsten Pr�sang and Bruno Donnadieu of UCR assisted with the study. The National Institutes of Health and the chemicals manufacturer Rhodia provided support.

The University of California, Riverside is a major research institution and a national center for the humanities. Key areas of research include nanotechnology, genomics, environmental studies, digital arts and sustainable growth and development. With a current undergraduate and graduate enrollment of nearly 17,000, the campus is projected to grow to 21,000 students by 2010. Located in the heart of inland Southern California, the nearly 1,200-acre, park-like campus is at the center of the region's economic development. Visit www.ucr.edu or call 951 UCR-NEWS (827-6397) for more information. Media sources are available at http://mmr.ucr.edu/experts/.


Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us